Clinical Trials
43 trialsthe Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
ADVANCE
Spectrum Pharmaceuticals, Inc
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Dong-A ST Co., Ltd.
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Peking University
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Asan Medical Center
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Canadian Cancer Trials Group
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Tianjin SinoBiotech Ltd.
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
Gema Biotech S.A.
PROTECT2
Sandoz
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
Jiangsu T-Mab Biopharma Co.,Ltd
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
PROTECT-1
Sandoz
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
BioLab 612 LLC
Limiting Chemotherapy Side Effects by Using Moxa
East and North Hertfordshire NHS Trust
PIONEER
Sandoz
A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
National Cancer Institute (NCI)
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
Amgen
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
Memorial Sloan Kettering Cancer Center
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
European Organisation for Research and Treatment of Cancer - EORTC
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
National Cancer Institute (NCI)
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
AviGenics
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Amgen
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
Amgen
Treatment for Elderly Patients With High Risk Breast Cancer
Amgen
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Institutes of Health Clinical Center (CC)
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
Maxygen Holdings Ltd.
A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
Tri-Service General Hospital